期刊
ONCOTARGET
卷 7, 期 22, 页码 33192-33201出版社
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.8899
关键词
glioblastoma; PIM kinase; mTOR signaling; p110 alpha
资金
- Hyundai Hope on Wheels Grant Program
- National Institutes of Health [CA121192, CA77816]
- Department of Veterans Affairs [I01CX000916]
- National Institutes of Health/National Cancer Institute [T32 CA09560]
- Cancer Center Support Grant [NCI CA060553]
The PIM family of proteins encodes serine/threonine kinases with important roles in protein synthesis and cancer cell metabolism. In glioblastoma (GBM) cell lines, siRNA-mediated knockdown of PIM kinases or pharmacological inhibition of PIM kinases by SGI-1776 or AZD-1208 results in reduced phosphorylation of classic PIM effectors and also elements of the PI3K/mTOR pathway, suggesting interplay between PIM and mTOR signals in GBM cells. Combination of PIM kinase inhibitors with BYL-719, an inhibitor specific for the PI3K catalytic isoform p110 alpha, results in enhanced antineoplastic effects in GBM cells. Additionally, pharmacologic inhibition of PIM kinases impairs growth of patient-derived glioma sphere cells, suggesting an important role for PIM kinases in cancer stem cell (CSC) function and survival. Such effects are further enhanced by concomitant inhibition of PIM kinase and p110 alpha activities. Altogether these findings suggest that pharmacological PIM targeting in combination with PI3K inhibition may provide a unique therapeutic approach for the treatment of heterogeneous tumors containing populations of therapy-resistant CSCs in GBM.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据